Helen Susan Kim

Filings by Helen Susan Kim span 4 companies, the busiest being Kite Pharma, Inc., Kosan Biosciences Inc and Applied Molecular Transport Inc. Over a trading history stretching from 14 March 2008 to 12 January 2026, the count stands at 80 filings.

On the open market, the record shows 13 purchases worth €12.9M and 45 sales worth €25.4M. Netting one side against the other leaves €12.4M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants and 14 option exercises. 2026 to date brings 2 purchases and no sales.

In size, the median ticket on the buying side is €1,183.

On 12 January 2026 came the latest disclosure, a transaction in Aktis Oncology, Inc. The most recent open-market purchase was published on 12 January 2026, 285 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.